Literature DB >> 8410139

Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)).

M Tada1, K Suzuki, Y Yamakawa, Y Sawamura, S Sakuma, H Abe, E van Meir, N de Tribolet.   

Abstract

The production of interleukin 8 (IL-8), a neutrophil chemotactic factor, and its amino acid sequence were examined in glioblastoma cell lines in vitro. Neutrophil chemotactic activity was demonstrated in 9 conditioned media of 15 human glioblastoma cell lines. Tumor necrosis factor (TNF)-alpha stimulated secretion of the activity in 7 lines and induced secretion in 4 other lines. ELISA quantification disclosed that the conditioned media contained interleukin 8 (IL-8) in an amount equivalent to the chemotactic activity. The IL-8 secretion increased with the stimulation by TNF-alpha. Northern blot analysis and the RT-PCR method confirmed expression of mRNA in the glioblastoma cells and its augmentation by TNF-alpha and/or IL-beta. Reversed-phase HPLC following ion-exchange chromatography revealed that the chemotactic activity was a single peptide, which was determined to be IL-8 by the retention time and ELISA. Furthermore, amino acid analysis disclosed that a major part of the glioblastoma-cell derived IL-8 peptide was 77 amino acid IL-8 (IL-8(77); with the N-terminal sequence AVLPRSAKELRCQCI-).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410139     DOI: 10.1007/bf01324831

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity.

Authors:  J M Schröder; U Mrowietz; E Morita; E Christophers
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

2.  Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma.

Authors:  M Yoshida; H Matsuzaki; K Sakata; M Takeya; K Kato; S Mizushima; M Kawakita; K Takatsuki
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

3.  Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor.

Authors:  C G Larsen; A O Anderson; J J Oppenheim; K Matsushima
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

4.  Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes.

Authors:  A Walz; P Peveri; H Aschauer; M Baggiolini
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

5.  Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells.

Authors:  V M Elner; R M Strieter; S G Elner; M Baggiolini; I Lindley; S L Kunkel
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

6.  Human neutrophils exhibit disparate chemotactic factor gene expression.

Authors:  R M Strieter; K Kasahara; R Allen; H J Showell; T J Standiford; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1990-12-14       Impact factor: 3.575

7.  The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8.

Authors:  J Van Damme; B Decock; R Conings; J P Lenaerts; G Opdenakker; A Billiau
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

8.  Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of beta-thromboglobulin.

Authors:  J Van Damme; J Van Beeumen; R Conings; B Decock; A Billiau
Journal:  Eur J Biochem       Date:  1989-05-01

9.  The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis.

Authors:  K Saukkonen; S Sande; C Cioffe; S Wolpe; B Sherry; A Cerami; E Tuomanen
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

10.  Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response.

Authors:  A Waage; A Halstensen; R Shalaby; P Brandtzaeg; P Kierulf; T Espevik
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

2.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

Review 3.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 4.  Current challenges in designing GBM trials for immunotherapy.

Authors:  Shiao-Pei Weathers; Mark R Gilbert
Journal:  J Neurooncol       Date:  2015-01-11       Impact factor: 4.130

5.  A novel human glassy-cell carcinoma cell line producing IL-6 and IL-8 from uterine cervix.

Authors:  A Oki; M Nishida; T Satoh; H Tsunoda; K Kasahara; K Saijo; T Kubo; T Ohno
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-04       Impact factor: 2.416

Review 6.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

7.  miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.

Authors:  Krishan Jethwa; Jun Wei; Kayla McEnery; Amy B Heimberger
Journal:  Clin Investig (Lond)       Date:  2011-12

8.  Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-κB.

Authors:  Shan Sun; Qiuwei Wang; An Giang; Cong Cheng; Chia Soo; Cun-Yu Wang; Linda M Liau; Robert Chiu
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

9.  Immunotherapy for malignant glioma.

Authors:  Carter M Suryadevara; Terence Verla; Luis Sanchez-Perez; Elizabeth A Reap; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Surg Neurol Int       Date:  2015-02-13

10.  High gene expression levels of VEGFA and CXCL8 in the peritumoral brain zone are associated with the recurrence of glioblastoma: A bioinformatics analysis.

Authors:  Xiaobin Luo; Shangyi Xu; Yali Zhong; Tianqi Tu; Youlin Xu; Xianglong Li; Bin Wang; Fubing Yang
Journal:  Oncol Lett       Date:  2019-10-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.